Wellness startup Biopeak raises $3.5 million in seed funding from Ranjan Pai office, Accel's Prashanth Prakash, others

Representative image

Bengaluru-based wellness and longevity startup Biopeak has raised $3.5 million in seed funding from Accel founding partner Prashanth Prakash, Claypond Capital (the family office of Manipal Group chairman Ranjan Pai), and NKSquared, the investment vehicle of Zerodha co-founder Nikhil Kamath.

The company will use the funds to expand its clinic presence across key cities and further develop its science and AI platform, which supports its diagnostic and care delivery model, co-founder and CEO Rishi Pardal said.

Founded in 2024 by Pardal and Shiva Subramanian, Biopeak provides personalised health services through in-house clinics. Its approach combines molecular diagnostics, high-resolution imaging, and non-invasive testing to assess early signs of physiological changes. The company opened its first clinic in Bengaluru in March 2025.

At the core of Biopeak’s offering is a diagnostic system that includes tests like organic acid profiling, microbiome mapping, salivary cortisol rhythms, and whole-exome functional genomics. These are paired with imaging tools such as MRI, CT, DXA, and ECHO, as well as tissue-level screenings that examine markers like mineral levels, toxin load, and oxidative stress.

“We’re at a rare moment in time- where advances in molecular science, AI, and diagnostic precision now make it possible to understand the body like never before and take highly customised, timely actions to maximise your healthspan. Biopeak, with its deep science and multidisciplinary team of experts, turns insight from your body into action and measurable outcomes. The moment is now to take control of your healthspan—because the tools and the science have finally aligned," Pardal said.

Each client typically undergoes over six hours of multidisciplinary consultations, guided by a dedicated health manager and a team of specialists. The resulting health plan is revisited over time and refined through follow-up testing.

Biopeak primarily serves two categories of users: those seeking to improve overall health and performance, and individuals managing chronic or complex conditions that may not be adequately addressed by conventional treatment.

The company is also working with institutions like the Indian Institute of Science (IISc) and Longevity India to adapt its models to South Asian health profiles and environments, aiming to improve relevance and accuracy in care.

“As India’s population ages, our greatest opportunity lies in building systems that not only extend life but enhance the years lived in strength, clarity, and purpose. Investing in geroscience, early interventions, and scalable research will be key to ensuring that longevity becomes a foundation for national wellbeing—not a burden on it," said Accel's Prashanth Prakash, who is also a mentor to Biopeak and Founding Patron of Longevity India, a platform focused on advancing research and interventions tailored to India’s ageing population.